|
|
Volumn 35, Issue 5, 2009, Pages
|
|
New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADAMANTANE;
ALOGLIPTIN;
ANTIDIABETIC AGENT;
DIPEPTIDE;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
DRUG DERIVATIVE;
GLUCAGON LIKE PEPTIDE 1;
INCRETIN;
PIPERIDINE DERIVATIVE;
SAXAGLIPTIN;
URACIL;
CLINICAL TRIAL;
HUMAN;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PATHOPHYSIOLOGY;
PATIENT EDUCATION;
PHYSIOLOGY;
REVIEW;
ADAMANTANE;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDES;
DIPEPTIDYL-PEPTIDASE IV INHIBITORS;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
HYPOGLYCEMIC AGENTS;
INCRETINS;
PATIENT EDUCATION AS TOPIC;
PIPERIDINES;
URACIL;
MLCS;
MLOWN;
|
|
EID: 73349116624
PISSN: None
EISSN: 15546063
Source Type: Journal
DOI: 10.1177/0145721709342900 Document Type: Review |
|
Times cited : (7)
|
|
References (101)
|
